Friday, July 10, 2026

pharma · Kidney Dysfunction · Obesity

LianBio

Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 dru

CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
2019
Employees
47
Programs
28
Drugs
40
Patents
0
Clinical program

Bupivacaine Liposome Injection

Approved · small molecule · Local Analgesia Via Infiltration

Bupivacaine Liposome Injection for Local Analgesia Via Infiltration is a Approved program (small_molecule) at Jian Li with 1 ClinicalTrials.gov record(s).

← All Jian Li projects Approved small molecule active

Internal code ZYWB-ZM-AHP-A-003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Jian Li
Phase
Approved
Modality
small_molecule
Indication
Local Analgesia Via Infiltration
Status
active
Trials
1